within 48 h after successful, early primary percutaneous coronary intervention (PCI) and at 9 weeks follow-up.
Methods

Population
We studied 12 patients (1 female), mean [± standard deviation (SD)] aged 58±10 years, out of a total of 65 consecutive patients with AMI suitable for primary PCI. The patients selected were all nondiabetics, admitted to the Coronary Care Unit (CCU) between September 2002 and October 2004 with a FAMI, and had undergone primary PCI within 5 h (3.2±2.4) from the onset of symptoms. All FAMI patients had 1-vessel coronary disease, and all had primary successful PCI with stenting, with final Thrombolysis In Myocardial Infarction (TIMI) flow 3 and no important complications.
As controls we studied 12 patients (3 females), aged 59.8±8 years, 11 with chronic stable angina, without a history of diabetes mellitus or myocardial infarction (MI) [left ventricular (LV) ejection fraction 61±3%], with severe 2-or 3-vessel coronary disease and positive exercise stress test (3 of whom performed the test the day after successful elective PCI with stenting), and 1 patient who had been admitted to the CCU with a diagnosis of Printzmetal's variant angina because of recurrent episodes of myocardial ischemia.
On admission, 7 FAMI patients had diagnostic elevation of the ST segment on anterior ECG leads and 5 had the change on the inferior ECG leads; the infarct-related artery was the left anterior descending artery in 6 patients, a dominant right coronary artery in 4, and a dominant left cir- Nine patients developed pathological Q waves within 24 h of the onset of chest pain; LV ejection fraction, determined by 2-dimensional (2D) echocardiography, after primary PCI, was 52±10%. All FAMI patients remained asymptomatic and were re-examined 9.6±4.3 weeks after discharge. Their major baseline characteristics are reported in Table 1 .
Protocol
FAMI group patients were maintained on aspirin, clopidogrel, -blocker or calcium antagonist and ACE inhibitors as required. A 24-h Holter monitoring was recorded in all 24 patients, prior to the PET study. Myocardial [18-F]-FDG-PET scan was performed in the fasting state (12 h) within 48h after primary PCI and again after 8-12 weeks follow-up (9.4±4.3). Five patients were also studied at 1-year follow up.
In all patients anti-anginal medications (except sublingual nitroglycerine) were discontinued for 24 h preceding the PET studies and all abstained from drinking tea or coffee on the morning of the PET procedures.
In order to compare the magnitude and the segmental distribution of FDG uptake observed in the FAMI group with the uptake in a fed, normal individual, we selected 1 healthy volunteer (39-year-old male) in whom FDG was administered 1 h after a high-carbohydrate meal supplemented with 75 g glucose orally.
This study was approved by the Ethics Committee and written consent was given by all patients.
Coronary Angiography and LV Echocardiography
Selective coronary angiography was assessed by 2 experienced observers who were unaware of the clinical data.
Reperfusion of the infarct-related artery was defined according to the TIMI trial's score system. Resting 2D echocardiography was performed and analyzed according to standard methods. 15 Regional ventricular wall motion of each segment was assessed using a 4-point scoring system: 1=nor-mal, 2=hypokinetic, 3=akinetic, 4=dyskinetic and 5= hyperkinetic. The LV volume at end-systole (ESV) and enddiastole (EDV), as well as the LV ejection fraction, were calculated.
PET Imaging
PET scans were performed with a whole-body PET/computed tomography (CT) scanner with 15-cm axial field of view (DISCOVERY LS-GE, Milwaukee, WI, USA) over the cardiac region. [16] [17] [18] In the present study, patients were fasting for at least 12 h before tracer injection. PET images were acquired in 2D mode with a static 10-min frame, starting 60 min after IV injection of 296-370 MBq (8-10 mCi) of [18-F]-FDG. Before PET acquisition, CT scanning (4 slice CT, 140 KV, 90 mA) was performed over the same region for attenuation correction and anatomical localization.
Transaxial images were reconstructed using iterative OSEM reconstruction (subset 28, 2 iteration) and corrected for photon attenuation using the CT scan. Transaxial cardiac images were then re-oriented into horizontal long-axis, vertical long-axis, and short-axis images with a thickness of 4.25 mm. 19 For each patient the FDG uptake was measured on 7 short-axis images (starting near the valve plane and proceeding towards apex). For each of the short-axis images, 4 regions of interest (ROI) were drawn on the anterior, lateral, inferior and septal walls; for each patient, the mean blood pool activity was measured by drawing a circular ROI on the LV cavity on 3 mid-ventricular short-axis slices. 19 Heterogeneity in FDG uptake is expressed as a coefficient of variation (CV=100×SD FDG uptake/mean FDG uptake) over 28 myocardial segments.
Patient
Definition of Culprit and Nonculprit Areas
For PET image analysis, 4 myocardial regions (anterior, lateral, inferior-posterior and septal) over 7 cross-sectional planes (28 total segments for patient) were delineated on the co-registered PET/CT images. Nonculprit areas were de- Average segmental fluoro-deoxy-glucose (FDG) uptake ratio (± standard error) of each segment to left ventricular cavity activity of culprit segments (a) and of nonculprit segments (b) in stable patients and first acute myocardial infarction (FAMI) patients (pts) at baseline and at 9 weeks' average follow-up (F-UP). In each patient, 4 myocardial regions (anterior, lateral, infero-posterior and septal) over 7 cross-sectional planes, from base (B) to apex (A), were identified on the accompanying computed tomography scan.
fined as the regions of the heart wall not showing impaired regional wall motion on echocardiography, Q-waves on the ECG and not perfused by the infarct-related artery.
Blood Sampling
Plasma glucose concentration (mg/dl), serum concentration of insulin (IU/L), serum free fatty acid concentration (mmol/L) and homeostatic model assessment (HOMA) index [mean of 3 fasting insulin (mIU/L)× fasting glucose (mmol/L)/22.5], and circulating levels of high-sensitivity C-reactive protein, interleukin (IL)-6 and IL-10 were determined at the time of tracer injection.
Plasma glucose was measured by the glycosidase method using a Beckman Glucose Analyzer II (Beckman Instruments), and the total and high-density lipoproteincholesterol levels and that of triglycerides were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim). C-reactive protein levels were determined with high-sensitivity latex-enhanced immunonephelometry on a Behring BN II Nephelometer (Dade Behring; lower sensitivity 0.1 mg/L, intra-assay and interassay coefficients of variation 3.3% and 3.2%, respectively).
IL-6 and IL-10 were measured with a commercial assay kit (Quantikine human IL-6-IL-10 R&D System, Minneapolis, MN, USA). 20 Adiponectin, resistin and plasminogen-activator inhibitor-1 (PAI-1) levels were assessed with a commercial assay kit (Human serum adipokine, Licoplex kit, Linco Research, MO, USA). [21] [22] [23] [24] 
Statistical Analysis
All data are presented as mean ± SD, if not otherwise specified. The unpaired Student's t-test was used to assess . In both the culprit and nonculprit areas the FDG uptake was lower than left ventricular cavity activity in 10-15% of the segments, while it was more than 2-fold greater in 30-40%. differences in mean values between groups. Correlations between blood sampling data and FDG uptake were made using Pearson's correlation coefficient. A p value of less than 0.05 was considered to indicate statistical significance.
Results
There were no significant differences in age, sex and risk factor prevalences between controls and FAMI patients. No patient had symptoms or ischemic changes on the 24-h Holter recordings obtained immediately prior to the PET study. Our study showed a striking multifocal increase of cardiac FDG uptake in the LV walls of the FAMI patients with successful primary PCI studied 48 h from symptoms onset, compared with the controls. The average uptake of the total 336 LV wall segments defined on the PET/CT images of the 12 FAMI patients was 1.28±0.57-fold higher than the activity present in the LV cavity. By contrast, the average uptake of the 336 segments of the 12 control patients was only 0.70±22 (p<0.001) (Figs 1a,b) . The segmental FDG uptake in the FAMI patients was multifocal in both the culprit and nonculprit areas (Figs 1a,b, 2, 3) . Overall, it was less than the activity present in the LV cavity in 38% of the segments; was 1-2-fold greater in 51.8% and more than 2-fold greater in 10.2%. The normal individual studied after glucose load had a homogeneous segmental LV wall FDG uptake in all 28 segments, approximately 3-fold higher than the LV cavity activity. Thus, in the FAMI patients, both culprit and nonculprit areas of FDG uptake of each segment could range from levels similar to that of controls to levels 2-3-fold higher, in the range of those observed in a normal individual after glucose load.
A segmental cardiac wall uptake higher than that of the ventricular activity was not related to culprit or nonculprit areas, as it was observed in 62.3% of the segments in culprit areas (81 of the total 130 culprit segments, mean 6.5±5 segments per patient) and in 66% of those in nonculprit areas (136 of the total 206 nonculprit segments, mean 11.3±8.6 segments per patient). In particular, an elevated FDG uptake in culprit areas ranged between 0 segments in 1 patient to 16 segments in 2 patients, and in nonculprit area between 0 in 1 patient to 22 segments in 2 patients (Table 2) . Also, the average magnitude of the uptake of the total segments belonging to culprit and nonculprit areas was similar (1.28±0.62 and 1.27±0.52, respectively; Figs 1a,b).
At 9-week follow-up, the multifocal pattern of cardiac wall FDG uptake persisted, mostly involving the same segments, and on average it was actually slightly, but significantly, increased in both culprit and nonculprit segments (1.49±0.57 and 1.81±1.46, respectively, p<0.01, compared with the acute study, Figs 1a,b) , with an average uptake in the total 336 LV wall segments of 1.69±1.15 (p<0.001).
The CV of the total 336 LV wall segments was 41.5% in the FAMI patients and 32.2% in the controls (p<0.001), and at follow-up was 67% in FAMI patients (p<0.001 for both comparison). In the culprit segments the CV was 44.5% and in the nonculprit segments it was 44.3% (p=NS). At followup the CV was 55% in the culprit segments and 68% in the non-culprit segments (p=NS). Compared with the acute phase, the CV of the nonculprit segments at follow-up was significantly increased (p<0.001).
At 1-year follow-up, FDG uptake, reassessed a third time in 5 patients, was no longer detectable in 2, but persisted with an unchanged segmental distribution, though reduced, in the other 3.
The number of segments and the magnitude of their FDG uptake in culprit and nonculprit areas in the acute and follow-up studies was not related to peak creatine kinase or to regional wall motion abnormalities.
There were no significant differences between FAMI and control patients in plasma levels of glucose, insulin, free fatty acids, HOMA index, adiponectin, resistin, PAI-1, IL-10, tumor necrosis factor-, and high-sensitivity C-reactive protein. Only admission IL-6 levels were significantly higher in the FAMI group than in the controls, but the difference disappeared at 3 months (Table 3 ). The lack of correlation between IL-6 levels and mean FDG uptake of all 28 myocardial segments of each patient was confirmed by the data shown in Fig 4. Only admission IL-6 levels were significantly higher in the FAMI patients than in the controls, but the difference disappeared at 3 months follow-up, whereas the mean FDG uptake of the FAMI patients remained persistently high.
In the FAMI group, cardiac FDG uptake in culprit and nonculprit segments on admission and at 3 months was not correlated with plasma free fatty acids, triglycerides, glucose, insulin, adiponectin, resistin, PAI-1 or HOMA index.
At 9-weeks follow-up, LV ejection fraction remained unchanged (55±9%) and no significant differences was found between values of EDV (119.9±30.9 ml vs 115±28 ml) and ESV (83.5±34 ml vs 79±30 ml) or regional wall motion abnormalities, between the acute and follow-up period. The LVEF, EDV and ESV of the control patients were 55±9%, 98.7±22 ml and 69±28 ml, respectively. Maximal ECG stress test was negative in all FAMI patients during followup. During 1-year follow-up, no FAMI patients developed coronary instability and all remained symptom free.
Discussion
Our study showed that patients with their FAMI and 1-vessel disease exhibited an intense, multifocal FDG uptake in multiple segments of infarct-related and of non-infarctrelated areas of the LV wall, within 48 h after successful early primary PCI, confirming and extending previous findings. 25, 26 This pattern of multifocal cardiac wall FDG uptake persisted with an increased average intensity at 9-weeks follow-up, and was still present, though attenuated, at 12-months follow-up in 3 of the 5 patients studied. The cause of these striking and consistent findings can only be speculative, but its understanding could stimulate research on yet unexplored pathogenetic components of coronary instability and of MI.
Potential Mechanisms of Multifocal, Persistent Cardiac FDG Uptake
Our findings in the FAMI patients cannot be accounted for by the presence of severe coronary atherosclerotic plaques or by the procedure of elective PCI with stenting, as no cardiac FDG uptake was detectable in stable patients requiring elective coronary revascularization, including those studied soon after elective PCI with stenting. Our observations are consistent with those of previous reports of increased FDG uptake in nonculprit areas in some patients with a recent history of ACS (2 or more weeks previously) 26 and of patients with unstable angina and 1-vessel disease who showed an enhanced cardiac FDG uptake in LV wall segments perfused by the culprit artery and also in segments perfused by nonstenotic arteries. 25 Myocardial glucose uptake can be stimulated by increased insulin levels, 27 which can be excluded in the fasting patients in the present study, and by persistent ischemia directly and indirectly in ischemic and also nonischemic areas. 26, 28 Alternatively, glucose uptake can be enhanced in inflammatory cells located in the coronary vessel wall and/or in the myocardium, and possibly also in the myocardiocytes and endothelial cells by pro-inflammatory cytokines. 29, 30 The persistence of the enhanced multifocal FDG uptake for several months has not been previous described and cannot be accounted for by a correlation with circulating free fatty acid levels, in agreement with a previous observation in ACS, 26 with IL-6 or with any of the other metabolic parameters assessed.
Possible Role of Ischemia
Cardiac FDG uptake was found to increase markedly in postischemic myocardium of fasting patients with stable CAD following effort-induced angina, 31 but the uptake was confined to postischemic areas, so transient ischemia induced by effort does not cause glucose uptake in nonculprit areas. No uptake was detectable in the present patients with active variant angina and repeated episodes of transmural ischemia. In experimental animals with persistent or prolonged ischemia, FDG uptake was observed also in nonischemic areas in the initial hours and days after reperfusion. In dogs, acute ischemia stimulates the expression of the gene encoding for the glucose transporter, GLUT-1, in ischemic and nonischemic myocardial regions. 28 However in 2 patients of the FAMI group the FDG uptake was confined to segments of nonculprit areas and we found no relation between peak CK-MB, global or regional ventricular dysfunction and the location or intensity of cardiac wall FDG uptake. Some patients with minimal elevations of CK-MB and of troponin I, with normal global LV function and no detectable compensatory hyperkinetic areas, had elevated FDG uptake confined to some segments of infarctor noninfarct-related areas. Thus the elevated FDG uptake in the FAMI patients in some segments of the nonculprit areas cannot be related to compensatory regional hypercontractility caused by ischemia. Moreover, this pattern of multifocal cardiac wall FDG uptake persisted, with an increased average intensity at 9 weeks follow-up, in contrast with the lack of significant variations in LV ejection fraction, EDV and ESV and regional wall motion abnormalities between the acute and follow-up phases. In this study we could not detect enhanced FDG uptake in the posteriorlateral wall, as reported by Gropler et al in quantitative studies. 32 
Possible Role of Inflammation
An inflammatory trigger appears a plausible explanation for the multifocal enhancement of cardiac glucose uptake. Pro-inflammatory cytokines are known to increase glucose uptake by inflammatory cells, macrophages and lymphocytes, 33 as well as in endothelial cells 29, 30 by stimulating the translocation of the glucose transporter GLUT-1 from the cytoplasm to the plasma membrane. Inflammatory cells may be located not only in coronary arteries and arterioles, but also in the myocardium. 6 An inflammatory process might also enhance glucose uptake in coronary endothelial cells and possibly in myocardiocytes.
An inflammatory trigger of glucose uptake would explain its multifocal distribution and variable intensity. The possibility of an initial inflammatory trigger would be consistent with the elevation of IL-6 plasma levels on admission, but the persistence of elevated FDG uptake for several months requires the persistence of activated inflammatory cells or of enhanced expression of transmembrane glucose transporters in myocardiocytes and/or endothelial cells. This interpretation is consistent with the report of enhanced FDG uptake in nonculprit areas of patients with unstable angina, 26 and with widespread coronary, 1 microvascular, 5 and myocardial 6 inflammation previously described, and with the reduced vasodilator response, also in non-infarct related coronary vascular beds, up to 6 months after acute infarction. 34 However, inflammatory biomarkers alone, without histopathological studies, are insufficient to support this hypothesis. Moreover, increased FDG uptake at 9 weeks followup occurred despite reduced circulating IL-6 levels.
Study Limitations
Cardiac FDG uptake was assessed semi-quantitatively, as a ratio of wall segments to cavity activity. However, a quantitative assessment would not have influenced the 2 major findings of our study: the persistence of elevated FDG uptake in both culprit and nonculprit areas and its nonuniform, multifocal distribution and variable intensity. Similarly, plasma catecholamine levels, unfortunately not reported in this study, which are usually transitorily higher during AMI, cannot explain the persistence of elevated FDG uptake at follow-up. The very low incidence of episodes of recurrent coronary instability during follow-up, possibly related to aggressive and comprehensive treatment, prevents an assessment of the prognostic implications of our findings.
A further limitation of our study is the need for an explanation of the simultaneous persistence or even increased FDG uptake at follow-up in the presence of reduced levels of circulating IL-6.
Conclusions
We found a multifocal, noninfarct-related, cardiac FDG uptake immediately after AMI, which persisted to followup. The cause of these striking and consistent findings is still speculative. The possibility of a very persistent, nonuniform, enhanced expression of transmembrane glucose transporters in inflammatory cells and/or myocardiocytes and endothelial cells could be assessed by appropriate histopathological molecular biology studies. Understanding the causes of a potential widespread multifocal persistent cardiac inflammation could open the way to novel diagnostic, therapeutic and preventive strategies in ACS.
